Physician profile
Prudencio Samson
NPI 1013045863
$4,901.57
in general payments reported to CMS, 2019-2025
21 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $318 · 2021: $771 · 2022: $724 · 2023: $1,075 · 2024: $1,035 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,277.83 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $678.27 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $356.97 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $348.25 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $323.41 | 2019-2023 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $203.69 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $167.46 | 2020-2022 | |
| Allergan, INC. | $86.21 | 2019-2020 | |
| Indivior INC. | $68.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $51.17 | 2019-2020 | |
| Axsome Therapeutics, INC. | $50.88 | 2024-2025 | Auvelity |
| Hologic Sales and Service, LLC | $49.06 | 2023-2024 | Aptima |
| Eisai INC. | $36.71 | 2020 | |
| Aimmune Therapeutics, INC. | $28.51 | 2025 | Zenpep |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.78 | 2024 | Bexsero |
| E.R. Squibb & Sons, L.L.C. | $23.32 | 2024 | Cobenfy |
| Merck Sharp & Dohme LLC | $22.22 | 2023 | Gardasil 9, Vaxelis, Rotateq |
| Cranial Technologies, INC | $17.71 | 2025 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $17.53 | 2019 | |
| Acadia Pharmaceuticals INC | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prudencio Samson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.